BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15547174)

  • 1. Silencing the critics: new studies move closer to answering epigenetic questions.
    Tuma RS
    J Natl Cancer Inst; 2004 Nov; 96(22):1652-3. PubMed ID: 15547174
    [No Abstract]   [Full Text] [Related]  

  • 2. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.
    Fahrner JA; Eguchi S; Herman JG; Baylin SB
    Cancer Res; 2002 Dec; 62(24):7213-8. PubMed ID: 12499261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
    Deng G; Chen A; Pong E; Kim YS
    Oncogene; 2001 Oct; 20(48):7120-7. PubMed ID: 11704838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
    Cameron EE; Bachman KE; Myöhänen S; Herman JG; Baylin SB
    Nat Genet; 1999 Jan; 21(1):103-7. PubMed ID: 9916800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic cancer therapy makes headway.
    Mack GS
    J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
    [No Abstract]   [Full Text] [Related]  

  • 8. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 9. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
    Deng G; Chen A; Hong J; Chae HS; Kim YS
    Cancer Res; 1999 May; 59(9):2029-33. PubMed ID: 10232580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of the MLH1 gene in hematological malignancies.
    Matsushita M; Takeuchi S; Yang Y; Yoshino N; Tsukasaki K; Taguchi H; Koeffler HP; Seo H
    Oncol Rep; 2005 Jul; 14(1):191-4. PubMed ID: 15944788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy.
    Nyce JW
    Mutat Res; 1997 Apr; 386(2):153-61. PubMed ID: 9113116
    [No Abstract]   [Full Text] [Related]  

  • 14. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Modulators and the New Immunotherapies.
    Dear AE
    N Engl J Med; 2016 Feb; 374(7):684-6. PubMed ID: 26886527
    [No Abstract]   [Full Text] [Related]  

  • 16. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer.
    Leung WK; Yu J; Bai AH; Chan MW; Chan KK; To KF; Chan FK; Ng EK; Chung SC; Sung JJ
    Mol Carcinog; 2003 Jun; 37(2):91-7. PubMed ID: 12766908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
    Christman JK
    Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
    Stresemann C; Lyko F
    Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Chan DW; Lee JM; Chan PC; Ng IO
    Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation and gene silencing in cancer.
    Baylin SB
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.